Clinical trial NCT01593410 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lenalidomide, dexamethasone
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. Understand and voluntarily sign informed consent form

          2. Age ≥ 18 years at the time of signing consent

          3. Prior or current diagnosis of Durie-Salmon Stage II or III multiple myeloma AND have
             disease progression after at least 2 cycles of systemic anti-myeloma treatment or have
             relapsed with progressive disease after treatment.

          4. Measurable levels of myeloma paraprotein in serum (≥ 0.5 g/dL [5 g/L] or urine (≥ 0.2
             g excreted in a 24-hour collection sample).

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          6. Able to adhere to the study visit schedule and other protocol requirements.

          7. Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan
             requirements.

        Exclusion Criteria

          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from participating in the study.

          2. Subjects with non-secretory multiple myeloma by Serum Protein Electrophoresis (SPEP)
             and Urine Protein Electrophoresis (UPEP) assessment.

          3. Pregnant or lactating females

          4. Any of the following laboratory abnormalities:

               -  Absolute neutrophil count of < 1000 cells/mm3 (1.0 X 109/L)

               -  Platelet count < 50,000/mm3 (50 X 109/L) in subjects in whom < 50% of the bone
                  marrow nucleated cells were plasma cells

               -  Renal failure requiring dialysis or peritoneal dialysis

               -  Serum glutamic oxaloacetic transaminase, (SGOT)/ Aspartate-Aminotransferase (AST)
                  > 3.0 x upper limit of normal (ULN)

               -  Serum total bilirubin > 2.0 mg/dL (34μmol/L)

          5. Any condition, including the presence of laboratory abnormalities, which placed
             subject at unacceptable risk if participating in the study or which would confound the
             ability to interpret study data.

          6. Significant active cardiac disease within the previous 6 months.

          7. Prior history of malignancies, other than multiple myeloma, unless the subject has
             been free of disease for ≥ 3 years. Exceptions include the following:

               -  Basal cell carcinoma of the skin

               -  Carcinoma in situ of the cervix

               -  Carcinoma in situ of the breast

               -  Squamous cell carcinoma of the skin

          8. Incidental histologic finding of prostate cancer (Tumor, Node, and Metastasis [TNM]
             stage of T1a or T1b)

          9. Known hypersensitivity to thalidomide or dexamethasone

         10. Prior history of uncontrollable side effects to dexamethasone therapy

         11. Peripheral neuropathy ≥ grade 2

         12. Prior use of lenalidomide

         13. Use of any standard/experimental anti-myeloma drug therapy within 28 days of the start
             of study drug or use of any experimental non-drug therapy (e.g. donor
             leukocyte/mononuclear cell infusion) within 56 days of the start of study drug)

         14. Unable or unwilling to undergo antithrombotic therapy

         15. History of deep vein thrombosis (DVT) or pulmonary emboli (PE) within the past 12
             months

         16. Known HIV positivity

         17. Active infectious hepatitis A, B, or C or chronic carriers of hepatitis B with
             hepatitis B surface antigen (HBsAG) positive or if the hepatitis B viral
             deoxyribonucleic acid (HBV DNA) level is detectable by polymerase chain reaction
             (PCR).